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From Materia Medica to the Pharmacopoeia: Challenges of
Writing the History of Drugs in India
Nandini Bhattacharya*
University of Dundee
Abstract
Historians of indigenousmedicine in colonial India have lookedmore closely at the changes, reinventions
and reformulations of institutions of Ayurveda and Unani than at the cognitive content of the drugs
themselves. The few historians who have examined the changing content of indigenous medicines have
conceptualised the creation of materia medica of Indian drugs through two tropes: one of circulation
(of specific drugs) through epistemological and geographic boundaries and the second, of marginalisation
of certain other drugs either through a lack of textual legitimacy or the lack of the newly discovered ‘ac-
tive principles’ within each drug. While these approaches have been useful, there is a case to be made for
understanding the creation of formularies of Indian drugs in 19th and 20th centuries through the prism of
medical praxis in India.
This essay engages with the problem of providing a historical narrative of drugs and therapeutic
commodities in colonial India. This involves locating the histories of drugs within the
conventional divides of ‘western’ and ‘indigenous’ medicine in colonial India. In the process,
it will analyse the meanings of the multiplicity of drugs in the Indian market, the inclusions
and exclusions of drugs from the formal and informal formularies, and explore the principal
themes of circulation, marginalisation and formalisation of drugs in both text and praxis in
colonial India. All of these were involved in the journey from numerous materia medica to the
Indian Pharmacopoeia. An official Indian Pharmacopoeia was first published in 1955. There
were, however, several materia medica and accounts of the ‘indigenous’ drugs of India from
the 16th century onwards, and these became numerous in the 18th and 19th centuries. An
exploration of the materia medica of colonial India, therefore, reveals not only the thousands of
drugs, botanical, mineral and animal that were indigenous to India, but also reveals a history
of the epistemological changes in both western and Indian therapeutics in this period.
Harkishan Singh, who has written extensively on the histories of the Indian pharmaceutical
industry, pharmacy and pharmacopoeia in India, has tended to list the numerous pharmacopoeia
in a chronological fashion and argued for the linear progression of Indian drugs in the British
Pharmacopoeia (B.P.) from the time of the European discovery of indigenous drugs. This
triumphant and seemingly uninterrupted journey, according to Singh, had culminated in the first
official Indian Pharmacopoeia of 1955.1 This progression towards an Indian Pharmacopoeia,
borrowing from and adding drugs of common use by the Indian practitioners, involved the
gradual extension of the British pharmacopoeia to include some of these drugs. It was finally
fulfilled with the compilation of an Indian Pharmacopoeia. The exclusions and marginalisation
from the official formularies are of as much historical consequence as the inclusions of Indian
drugs within the British Pharmacopoeia and the publication, finally, of an Indian Pharmacopoeia.
Apart from Singh’s work, we do not have histories of the making of the Indian
pharmacopoeia. In general, historians of indigenous medicine in South Asia have argued for
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the reformulation of the collective identities of the practitioners of Indian medical systems.
These, they have argued, (with different regional variations) were facilitated by a vibrant
vernacular and regional press, institutionalisation of their pedagogy through streamlining both
texts and the practical lessons, reformulation of their packaging and use of innovative and
modern marketing techniques – all of which were given an emotive edge by aligning Ayurveda
and Unani with nationalist self-assertion.2
The rich historiography of indigenous medicine, therefore, has succeeded in highlighting the
problematics of modernising the pre-modern histories of indigenous medicine. David
Hardiman has pointed out that the revival of indigenous medical systems, both Ayurveda and
Unani-Tibb, involved reinventing (or to borrow Charles Leslie’s term from his
pioneering article), reviving Indian medical systems into new forms.3 This involved formulating
both Ayurveda and Unani-Tibb as cogent medical systems with a well-defined structure.
Hardiman has, following Romila Thapar’s work on the Hindu syndication, suggested that both
Unani-Tibb and more tortuously, Ayurveda, were reformulated in colonial India: first, through
Orientalist examinations from ancient and mediaeval scripts and second, through Unani and
Ayurvedic practitioners themselves from the 1930s. These projects assumed both a corporate
consensus and a ‘rational’ and ‘scientific’, Enlightenment method in order to first locate and
then historicise their principal texts. Historicising the texts, of course, was difficult; not only
were ‘ancient’ Sanskrit medical texts hard to obtain in the 19th century, but the few available
were held within families who practised Ayurveda and were unwilling to disseminate that
knowledge. Hardiman has argued that the reinvention of both Ayurveda and Unani as modern
medical systems remained and continues to be patchy, because of lack of strong state support
after independence as well as fragmented borrowings of biomedical therapies and technologies
on the part of the indigenous medical practitioners.
While the historians above have provided us with deep histories of the reinvention of
indigenous medicine in response to the challenges of the state-patronised western medical institu-
tions, they have paid curiously scant attention, with a few exceptions, to the materia medica – the
content of the drugs themselves. Therefore, in the histories of indigenous medicine mentioned
above, the cognitive content of the drugs themselves and their historic significance remain elusive.
There have been a few essays that historicize the journeys of drugs in colonial India. These
tend to focus on their circulation across geographical and epistemic boundaries (within the
indigenous medical paradigms), or refer to their marginalisation either in text or in practice.
Generally, the erasures were the consequence of the chemical revolution in the 19th century
that privileged the active principle within the drugs, relegating those drugs that were of
multifarious origins, plural uses and diverse scientific characteristics to obscurity.
Meanwhile, the essays that analyse the histories of the drugs themselves have focussed on two
principal themes: that of circulation of drugs and of the marginalisation of certain other drugs. Al-
though these have been treated in two different themes, I believe that both the circulation and the
marginalisation of specific drugs can be located within the problematic of the standardisation of
drugs and in a broader sense, the legitimacy (or otherwise) of indigenous drugs.
Circulation of Drugs Across Epistemic and Geographic Boundaries
Richard Grove’s works include Green Imperialism, where he ingeniously argues for a botanical
world-view of French and British imperialists in the 19th century, as evidenced by their
patronage of tropical gardens, conservation efforts (specifically in St Helena).4 Drawing on
the same theme, Grove has argued in a separate essay for a genealogy of global trade in
medicinal/botanical products and referred to the classification of drugs that occurred in the
17th century Goa.5 Garcia D’Orta’s Colloquis and the Dutch botanist Van Reede’s Hortus
Malabaricus were written in the context of the Portuguese and later, the Dutch global trade.
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Interestingly, however, he has also focussed on the marginal position and perspectives, of Garcia
D’Orta in particular, attributing these both to his hidden Jewish identity as well as his willingness
to consider local, indigenous knowledge that was not dependent on textual Arabic (Unani) or
even less on Ayurvedic practices. Grove’s work has situated the first ethno-botanies of the
Indian sub-continent in the context of a diffusion of indigenous botanical andmedical knowledge
into wider European medical and commercial networks. Grove’s essay, however, does not go
beyond a European perspective of indigenous drugs and their trade.
Guy Attewell’s essay ‘Interweaving Substance Trajectories’ is an example of a more recent
history of the circulation of drugs in the globalised world from the 18th to the 20th centuries.6
Through the prism of circulation, identification or misidentification Attewell untangles the
complex wanderings of the tahriq-al-fareek or the Venetian Treacle across cultural and
epistemic as well as social, temporal and geographical boundaries. In the process, he identifies
the single drug/substance theriac/or tiryaq-al-faruk (Anglicised treeak faruk), the transmission
of which encompassed pre-colonial Mughal, Deccan, Ottoman and Venetian trading networks
and made an irrelevancy, the author argues, of epistemological boundaries between
Unani/indigenous or western medicine. The treeak faruk, imported from Venice to
Masulipatnam through Arab traders in the 17th century, was used in British experiments with
‘native drugs’ in the 19th century Madras as a remedy for beri-beri. It has survived in contem-
porary Unani therapeutics as a remedy for the H1N1 virus. The contents of the theriac un-
doubtedly changed over its travels, both temporal and spatial. So did its value; a luxurious
commodity in the 18th century Hyderabad and used by princes as antidote to poisoning, it
was a common ‘native’ remedy for rheumatism and oedema in the 19th century. Attewell argues
for continuities: between trading networks of the 16th and the 19th centuries, as well as between
epistemic incorporations in apparently discrete materia medica through the example of this drug.
Other historians have discussed a similar circulation of drugs over geographies and
epistemological boundaries. Anna Winterbottom, for instance, has pointed out how the
botanical drug known as the ‘China root’ used from the 16th century onwards for syphilis and
related diseases was a valuable commodity that circulated across several trading networks in the
early modern world, from China to Persia, and from Cairo to Venice and Padua.7 The China
root, or the Smilax China, was traded from the Portuguese ports in the south-east, including Ma-
cau and Malacca to the west coast of India; from here, they entered the Indian bazaar or country
trade and were incorporated within Sanskrit and vernacular texts on Ayurvedic therapies and in
Persian texts on Unani medicines in the 16th century. So the China root circulated not only in
therapeutic texts but also in practice; it was extensively used in Safavid Persia and made entry into
Mughal-era therapeutic texts in the late 16th century. The British picked this up from their reg-
ular explorations within the Indian country trade in the 18th century, and at this time, it was used
extensively to cure syphilis; no other western drug was found to be as efficacious.
In the process, the China root emerges as both a changing ‘thing’ or material of the 18th cen-
tury global drugs trade as well as an illustration of a therapeutic product’s journey to oblivion with
its eventual substitution in the western pharmacopoeia with sarsaparilla in the 19th century. This
involved, Winterbottom has argued, political exigencies as well as modern scientific universalism.
Therefore, sarsaparilla, which had similar properties to the China root but could be cultivated
large-scale in the colonial West Indies, became a legitimate substitute for the China root, and
finally, when its active component ‘Perillin’ could not be found in the ‘original’ China root,
pharmacological science and political and economic opportunism both facilitated the expunge
of the China root from the British pharmacopoeia by 1914.
Both Attewell and Winterbottom have privileged circulation of drugs within the early
modern globalised world in their examination of the journeys of individual drugs. While
Attewell leaves out the question of politics of circulation altogether, Winterbottom locates
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the movement of meanings and content of drugs within economic and cultural frameworks that
made the difference between a drug’s continuity in the pharmacopoeia, leading us beyond a
simpler scientific model.
Selective Marginalisation of Drugs and the Certitude of ‘Active Principles’
Other historians have argued for the circulation of drugs as a process of their marginalisation. In
this, let us examine two other explorations of individual drugs: one within texts and the other in
therapeutic praxis. The first is Projit Mukharji’s essay on one ‘Vishalyakarani’, a mythological
drug referred to in many readings of the epic Ramayana.8 Mukharji draws upon the concept
of ‘retro-botanizing’ to deconstruct the historical narrative of the drug as an ancient Indian
therapeutic; instead, it emerges as a Brazilian drug that had been imported to India only after
the 15th century. Given contemporary political/nationalist discourse on the ancient nature of
indigenous drugs, the vishalyakarani fell between the opposing categories of either ‘indigenous’
or ‘western’ in any meaningful sense. This incapacity to obtain an ancient and ‘Indian’, textual,
Sanskrit lineage marginalised the drug in the newly reforming indigenous drugs’ movements
and their texts in colonial India. And to the extent, that indigenous drugs were visible in the
British Pharmacopoeia, vishalyakarani was marginalised at that site as well. Its textual disappearance,
nonetheless, did not obliterate its use in daily medical practice among Indian practitioners. Mean-
while, the quest for the ‘original’ vishalyakarani continues in contemporary Indianmedical discourse.
This trope of marginalisation occurs too in Pratik Chakrabarti’s investigation into the history of
another specific medicinal plant, the Swietenia febrifuga.9 It emerged out of an imperial imperative
to find viable and cheaper alternatives to the cinchona plant. The imperatives were commercial
and scientific, because in the 18th century, most of the wild cinchona existed in South America
which was outside the British imperium. Several alternatives to the cinchona were examined by
scientists across the British Empire in the 18th century, including the Cinchona officinalis and the
Cinchona caribeana as well as the Cinchona trif lora in the British colonies of St Lucia and Jamaica.
The Swietenia febrifuga was first discovered in Rajamundhry (present-day Andhra Pradesh) in
1793 byW.Roxburgh, an EIC surgeon and botanist. He sent it to Britain for scientific assessment
and recognition as a genuine substitute to cinchona. As Chakrabarti has pointed out, alternatives
to cinchona were an intensely competitive field in imperial scientific circles. Chakrabarti argues
that the isolation of the active principle, ‘cinchonine’ from the ‘original’ cinchona bark, relegated
all other cinchona substitutes to an ‘analytic contraction’ in scientific discourse and medical praxis.
This analytic contraction, he emphasises, was common tomany colonial and peripheral drugs, sci-
entific networks and researches; reduced to the clinical tests of the ‘active principle’ ingredients,
many drugs were either marginalised or ignored. In fact, the C. ledgeriana, a variety of cinchona
that yielded the greatest quality of cinchonine, was cultivated in Java and remained under the con-
trol of a Dutch cartel until the SecondWorld War.10 Therefore, the analytic contraction and the
legitimacy granted by the ‘active principle’ ingredient in each drug wrested drugs in the colonies
from their social and cultural contexts and rendered many of them irrelevant in the 19th century.
On a broader canvas, Chakrabarti has argued that the circulation of drugs within the globalised
world of the 18th century can only be understood in terms of the enrichment of both intellectual
and material wealth of European imperialism.11
The tropes of circulation and marginalisation have enriched our understanding of the
complexities of the making of an Indian materia medica. The trope of ‘circulation’ divests the
drugs from their political and cultural contexts and fails to note the marginalisation and erasure
of certain drugs. At the same time, I would argue also that too strong an emphasis on
marginalisations tend to obscure the nuances of the inclusions within the pharmacopoeia. These
nuances are significant because they carry within them the tortuous routes from indigenous
drugs to a more generic pharmacopoeia. An examination of these inclusions could as well relate
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a history of the power of the imperial knowledge to transform an indigenous drug to a
metropolitan one. One example is that of the seeds and oil of chaulmugra which was used
extensively by both Ayurveds and Hakims as a cure for leprosy. It was incorporated within
the British Pharmacopoeia, and in 1909, the German manufacturer Bayer had even obtained
a patent for it.12 Does the journey of chaulmugra from a bazaar drug to a patented therapeutic
by Bayer (an inclusion) can as well tell us something about power relations within the global
drugs market? Stuart Anderson, who in a brief article has explored the history of the British
Pharmacopoeia (B.P.) in India, emphasises that between 1868 and 1932, the B.P. (and its Indian
and colonial addendum, first published 1900) emerged as the standard of quality in medicines in
India.13 Therefore, the B.P. did become, he concludes, an imperial ‘tool’ and in turn was a
catalyst to the nationalist Indian demand for an Indian Pharmacopoeia. While Anderson is
correct in assuming that the B.P. was held to be the standard of dispensing medicine in colonial
India, his investigations have remained limited to the circulation of the B.P. and its special
colonial addendum. A closer attention to the medical market in India might enable historians
to rethink his assumption that in India, medicines were expected to be of British Pharmacopoeia
standard. In the absence of drug adulteration legislation of the kind prevalent in Britain, all drug
stores in India, including British-owned ones, sold medicines that did not conform to the B.P.
The B.P. was a hallmark of quality in name, but rarely available in fact.
Moreover, particularly between the two World Wars, research on the potency and charac-
teristics of Indian drugs occurred at various Indian medical research institutions, not all of them
motivated by cultural nationalism. Instead, the intense research and publications over the
legitimacy of specific Indian drugs, transcending cultural epistemologies of Ayurveda/Unani/
western therapeutics, seem rather to emphasise the richness and diversity of the Indian medical
market and the desire among medical researchers to harness these to enable the cheaper, easier,
more durable alternatives to imported medicines from Europe and elsewhere. Therefore, the
question of praxis remains critical in understanding the history of the Indian Pharmacopoeia.
Towards a History of the Indian Pharmacopoeia
In an attempt to resolve the challenge of writing the history of the Indian Pharmacopoeia, I
would like to query if it is possible to understand this history in a different form than the linear,
triumphalist history that Harkishan Singh provides.
The history of the Indian therapeutics has evolved along with the history of the Dutch and
British discovery of centuries-old Indian medical traditions. In that sense, Whitelaw Ainslie’s
Materia Medica of Hindoostan (1813) was the first collection that opened up the study of Indian
botanical therapeutics to the English speaking world.14 Ainslie, who was a surgeon at the Madras
medical establishment, wrote this as a useful catalogue ‘of such medicines of the British Materia
Medica, as are either the produce of Hindoostan, or brought to it from Asiatic countries, and are
to be met with in the Bazaars of populous Towns….’ This catalogue, an exhaustive list of the
medicines available in the bazaars and used by Indian and British medical men, was an eclectic
collection of botanical and mineral therapeutic products found in the local markets. And
although stating the botanical and English names for many products, pragmatically allowed for
the local names in Telugu, Tamil, Dakhini and Sanskrit for any drugs or minerals for those products
that for which he could not identify botanical names.His catalogue, published in two large volumes
of around 600 pages each, also identified British therapeutic products used by Indian physicians. In
that sense, Ainslie was the first historian of themedical praxis as evident in the medical marketplace.
Now, Ainslie’s work, with its textual and epistemological certitude, can also be read as the
beginning of the textual marginalisation of indigenous drugs. And this marginalisation occurred
also at the level of the dispensers of these drugs. Projit Mukharji has argued that ‘subaltern herb
gatherers’ were marginalised by Indian drug traders and pharmacists at this time.15 Similarly,
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Rachel Berger has argued that Indian drugs in general were written out of pharmacopoeia by
the late 19th century. However, as I have pointed out above, such an approach cannot explain
the retention of the various bazaar medicines in practice.16
This retention is evident in John Waring’s Remarks on the Uses of Some of the Bazaar Medicines
and Common Medical Plants of India published in 1859.17 Waring’s Bazaar Medicines proved
enormously popular and had made four editions by 1883. The first edition had been bi-lingual,
in Tamil and English, and printed for issuing to local vaccinators in the Madras medical
establishment. Local vaccinators evidently also functioned unofficially as both medical
practitioners and medical informants on local medical materials until the late 19th century. By
the third edition, Waring expected these formularies to be used widely in remote areas in India.
Thus, it is necessary to read Waring’s ‘bazaar’ as the site of the praxis of indigenous drugs, and
praxis therefore is key to explaining the emergence of the Indian Pharmacopoeia.
Perhaps this trajectory of an Indian pharmacopoeia will be clearer with an analysis of Kanny
Lall Dey’s more modest compilation. Dey was a western educated physician and a much-
respected member of the first Indian Medical Congress. His Indigenous Drugs of India: Short
Descriptive Notices of the principal medicinal products met with in British India was first published in
1867 and then revised and re-written in 1896. This represented his life-long aspiration to col-
lect, categorise and, finally, to fully integrate as many Indian drugs with western materia medica
as possible. In 1885, Dey was the only Indian nominated to the first of many committees by
the Government of India to make a comprehensive list of Indian medicinal plants.18 In 1899,
the Chemist and Druggist, a prominent trade journal published from Britain, dismissed the en-
deavour to integrate indigenous medicines within the British Pharmacopoeia: ‘so far, the com-
mittee has been little else than called into existence; it has met and corresponded, but does not
feel clear as to what it is all about, or how it can benefit mankind by investigating things that are
well known, so practically no useful end appears to have been served by the committee’.19
To return to the B.P., with its unprecedented colonial addendum, these were less celebrated
than might be expected in India, particularly by British officials, who largely dismissed them as ei-
ther academic or purely historical. An editorial in the Indian Medical Gazette even alleged that it
was not undertaken in consultation with the Government’s own committee on indigenous drugs.
The addendum, in any case, did not impact to any greater extent on the use of substitutes of west-
ern formularies with Indian ones already in use. Therefore, the textual marginalisation had little
effect on the use of the drugs within the medical market. Their marginalisation had already been
effected by this time.
This is apparent from a study of William Dymock’s compilation. After Ainslie’s work, the
next voluminous addition in English to the Indian materia medica was the William Dymock’s
Pharmacographica Indica.20 This was a four-volume magnum opus, and a follow-up of his The
Vegetable Materia Medica of Western India, published a decade previously.21 Dymock’s volumes
were a huge, collaborative attempt to document the botany of the Indian subcontinent as
comprehensively as possible. In this sense, they added to colonial epistemology in the same
way as the decennial census, the trigonometrical surveys and maps of the Indian sub-continent
over the 19th century. Dymock was exceptional by the late 19th century. J.F. Royle, whose
Essay on the Antiquities of Hindoo Medicine privileged ancient Indian medicine as historically
preceding Greek and Arabic medicine (in an evolutionary paradigm) nonetheless confined his
collection of ‘Hindu’ materia medica to materials within the London Pharmacopoeia (1851)
and British Pharmacopoeia (1864).22 There was a practical reason: the Bengal Board had
commissioned Royle to compile a list of drugs available in the Indian bazaars that might be
conveniently used as substitutes for the much more expensive imported items. Royle’s
Antiquities listed around 1000 botanical and mineral items sold in Indian bazaars as country
medicines. In hisManual of Materia Medica and Therapeutics, which went through several editions,
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Royle made it clear that his previous work was relevant to the extent that the histories of some
drugs ‘investigated by Hindoos’ and used in the present could be identified.23
Yet the volumes of the Pharmacographica Indica, unlike that of Royle’s compilation, reveals
more interesting ways in which the materia medica of India was evolving systematically towards
a framework of pharmacological knowledge that would eventually be divested from its social
and cultural roots. Therefore, historiographically, Dymock poses a problem. Can we take
Dymock’s account of ‘mythological’ and ‘historical’ Indian drugs as proof of western engage-
ment with Indian drugs, particularly in the context of their globalisation? Meanwhile,
Chakrabarti has pointed out that the discovery of the ‘active principles’ in therapeutic commod-
ities in the mid-19th century (caffeine from coffee, morphine from opium and, particularly,
quinine from cinchona) separated the drugs from their cultural origins and even more signifi-
cantly, from the political contexts of their discovery, and collection, and the processes through
which they were assimilated into western pharmacopoeia. No doubt this was a long and varying
process; Dymock’s Pharmacographia Indica claimed that the collection had put together scattered
publications on Indian pharmacopoeia, often from obscure sources, as well as ‘endeavoured to
collect and verify this information, and supplement it where deficient by original investigation
especially…the chemical composition and physiological action of the plants and drugs’. So far,
Dymock seems to have been in line with the general trajectory of dissociating drugs from their
broader contexts into chemistry-oriented formularies. British physicians and pharmacists,
including surgeons appointed at the governmentmedical hospitals, still used ‘bazaar’ or ‘country’
medicines when European drugs were not available when Pharmacographia Indicawas published.
There is no doubt that Dymock’s Pharmacopeia Indica was used regularly by pharmacists and
drugs merchants in the 19th century and the early 20th century India. The trade journal in
London,Chemist and Druggist, used Dymock’s work to emphasise the substitution of belladonna
with the indigenous datura fastuosa, a relatively new substitution.24 This, I suggest, was a different
kind of substitution from the 18th century bazaar substitutes used when European drugs were
not available – it involved a deeper ingraining of the Indian drugs market with the global
demands, and this was accepted by British authors of pharmacopoeia. This was a new globali-
sation of Indian drugs. As Kanny Lall Dey suggested in 1884, Calcutta had the potential of being
established as a ‘drug emporium which would be central to the great markets of the world....’25
But there is a disjuncture here. The preface to the Pharmacographia Indica itemises unexpected
materials that are difficult to fit into the above mentioned trajectory. ‘Plants of historical and
mythological origins’ write the authors, ‘are not omitted, as the history of Indian medicaments
would be incomplete without them.’ This presents us with a difficulty: was Dymock’s collec-
tion a pharmacopoeia or a history of materia medica in the Indian sub-continent, and if it was
both, does this subvert the linear account of the movement from materia medica to pharmaco-
poeia? Why in short, did Dymock devote so much time and energy to include ‘plants of histor-
ical and mythological origins’26? He confirmed that these ‘though possessing little or no
medicinal activity, have not been omitted, as the history of Indian medicaments would be in-
complete without them’. At the same time, Dymock articulated his wish to engage contempo-
rary (presumably western) medical practitioners with his collection and provided comparisons of
‘empirical estimates’ of drugs with modern pharmacological research. These included a lengthy
list of poisons as well as obscure drugs that were not used by Indians, such as the Meconopsis
Wallichii (112) which did not have a vernacular Indian name; or theKaff Maryam, imported from
Syria, and whose efficacy the author appears to have had no opinion of. One possibility is that
by enumerating the mythological or ‘historical’ drugs, Dymock sought to both demystify them
as well as emphasise their mythological nature. As for ‘historical’ drugs, cataloguing them
comprehensively served to highlight their contemporary irrelevance. In that sense, Dymock’s
work emerges as historical record as well as the guardian of contemporary formulary.
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In conclusion, I would argue that the various pharmacopoeia have to be historically
understood as the product of the drugs and therapeutics market in India, which was defined
as a regime of praxis. A history of the numerous pharmacopoeia, therefore, needs to look at
the structures of the drug market as well as the circulations and marginalisation in medical texts.
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